Post-therapeutic recovery of serum interleukin-35 level might predict positive response to immunosuppressive therapy in pediatric aplastic anemia
Authors:
- 17 February 2017
- journal article
- research article
- Published by Taylor & Francis in Hematology
- Vol. 22 (7) , 430-436
Abstract
Background: The predictive value of interleukin-35 (IL-35) on efficacy of immunosuppressive therapy (IST) in aplastic anemia (AA) has not been well investigated. The aim of the study was to evaluate the association between serum IL-35 level and response to IST in pediatric AA. Methods: A total of 154 children with AA and 154 controls were included between January 2012 and December 2013. Blood and bone marrow fluid specimens were collected. Serum level of IL-35 was determined by enzyme-linked immunosorbent assay. Patients were treated with IST, and response to therapy was evaluated during 180-day follow-up period after starting therapy. Results: Serum levels of IL-35 at admission decreased significantly in patients compared with that in controls (10.9 ± 5.5 pg ml−1 and 45.3 ± 8.8 pg ml−1, p < 0.001). After starting IST, serum levels of IL-35 in patients recovered 30.7 ± 9.7 pg ml−1 in the first 28 days (p < 0.001). During the follow-up period, increased range of serum IL-35 level ≥30.7 pg ml−1 in the first 28 days was associated with effective response to therapy (odds ratio 7.97, 95% confidence interval 3.82–16.79). In addition, Fas/FasL protein expression in bone marrow mononuclear cells dropped significantly in the same group of patients in the first 28 days (p < 0.05). Conclusion: The study revealed that post-therapeutic recovery of circulating IL-35 concentration might be an independent predictor for effective response to IST in pediatric AA. Moreover, apoptosis might be involved in such a forecasting process.Keywords
This publication has 30 references indexed in Scilit:
- Interleukin-35 Mediates Mucosal Immune Responses That Protect Against T-Cell–Dependent ColitisGastroenterology, 2011
- Cutting Edge: Human Regulatory T Cells Require IL-35 To Mediate Suppression and Infectious ToleranceThe Journal of Immunology, 2011
- Predicting response to immunosuppressive therapy in childhood aplastic anemiaHaematologica, 2011
- Alteration in Marrow Stromal Microenvironment and Apoptosis Mechanisms Involved in Aplastic Anemia: An Animal Model to Study the Possible Disease PathologyStem Cells International, 2010
- Primitive Sca-1 Positive Bone Marrow HSC in Mouse Model of Aplastic Anemia: A Comparative Study through Flowcytometric Analysis and Scanning Electron MicroscopyStem Cells International, 2010
- Guidelines for the diagnosis and management of aplastic anaemiaBritish Journal of Haematology, 2009
- Long-Term Outcome of Pediatric Patients with Severe Aplastic Anemia Treated with Antithymocyte Globulin and CyclosporineThe Journal of Pediatrics, 2008
- Epidemiology of aplastic anemia: a prospective multicenter studyHaematologica, 2008
- The inhibitory cytokine IL-35 contributes to regulatory T-cell functionNature, 2007
- Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant ErythropoietinNew England Journal of Medicine, 2002